首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1374807

全球腸道管理系統市場 -2023-2030

Global Bowel Management Systems Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

腸道管理系統 (BMS) 是一種臨時遏制裝置，適用於臥床或行動不便的失禁患者，腸道控制很少或沒有，糞便呈液體或半液體。它們也適用於嚴重燒傷患者，以管理其腸道功能，促進生殖器、會陰或肛門皮膚移植的癒合，並在整形手術後保持感染控制。

只有在考慮了所有其他大便失禁管理替代方案後，才應插入用於控制大便失禁的腸道管理系統。使用腸道管理系統必須在對患者進行全面評估後與負責患者護理的醫療團隊達成一致。

考慮到的病人：感染控制、設備相關皮膚破損的風險、隱私和尊嚴以及使用禁忌。

除了防止感染傳播之外，腸道管理系統還可以防止糞便細菌污染位於腹股溝區域的尿管、靜脈導管和動脈導管，導致局部和全身感染。

市場動態：促進因素與限制因素

技術進步和產品推出的興起

腸道管理系統的進步和主要參與者推出的新產品的增加將進一步推動預測期內的市場成長。

例如，2023 年 4 月，NHS 基金會信託旗下的數位健康公司 health call 推出了一個針對膀胱和腸道問題的自我推薦平台，讓用戶自行參考該信託網站的服務，而無需去看全科醫生。該平台簡化了尋求幫助和支持的過程，讓用戶提供準確、真實的推薦，這些推薦更容易被信託機構分類。

該平台於 2023 年推出，顯著改善了分診並加快了轉診速度，使患者能夠全天候 (24/7) 獲得服務。該解決方案還為轉介提供清晰的審計追蹤並加快流程。科技在膀胱和腸道護理方面發揮著越來越大的作用，九家 NHS 信託公司緊隨其後，英國新創公司 Motilent 則獲得了國家健康與護理研究所的資助。

此外，2022年2月，全球領先的造口護理產品製造商之一康樂保今年在新加坡推出了最新的創新產品SenSura Mio。新加坡是東南亞第一個推出 SenSura Mio 的國家，旨在改善造口者或經歷過造口但現在仍患有造口的人的生活品質。

此外，發炎性腸道病患疾病率的上升、老年人口的增加、各種腸道管理產品的推出、最近和新的潛在批准以及有利的報銷政策，將進一步推動預測期內的市場成長。

市場動態：克制

患者偏好大便失禁的非侵入性臨床治療。目前，大便失禁可以透過侵入性（手術）或非侵入性方式進行治療。手術治療的標準模式包括將生物材料注入肛管、肛管射頻治療、肛門肌肉損傷的手術修復、骶神經刺激、人工腸括約肌、肌肉轉位以強化肛門括約肌以及造口。這些往往需要患者長期康復，而且非常不方便，甚至非常痛苦。

此外，缺乏認知、監管擔憂和擔憂的副作用也是預測期內阻礙市場成長率的因素。

Bowel management systems (BMS) are temporary containment devices, indicated for bedridden or immobilised incontinent patients, with little or no bowel control, who have a liquid or semi-liquid stool. They are also indicated for patients with severe burns to manage their bowel function, promote healing of genital, perineal or anal skin grafts and maintain infection control following plastic surgery.

A bowel management system for the control of faecal incontinence should only be inserted once all other faecal incontinence management alternatives have been considered. The use of a bowel management system must be agreed upon with the medical team in charge of the patient's care following a holistic assessment of

the patient which has taken into consideration: infection control, risk of device-related skin breakdown, privacy and dignity, and contraindications for use.

In addition to preventing the spread of infection, a bowel management system can potentially prevent faecal bacterial contamination of urinary, intravenous and arterial catheters located in the groin area, causing local and systemic infection.

Market Dynamics: Drivers and Restraints

Rise in the technological advancements and product launches

The rise in the advancements in bowel management systems and novel product launches by key players will further drive the market growth during the forecast period.

For instance, in April 2023, NHS foundation trust owned digital health company health call launched a self-referral platform for bladder and bowel issues, allowing users to self-refer to services from the trust website without seeing their GP. The platform simplifies the process of seeking help and support, allowing users to give precise, factual referrals that are easier to triage by the trust.

The platform launched in 2023, has significantly improved triage and sped up referrals, allowing patients to access the service 24/7. Th,e solution also provides a clear audit trail for referrals and speeds up the process. Technology is playing a growing role in bladder and bowel care, with AI devices being trailed by nine NHS trusts and UK start-up Motilent receiving funding from the National Institute for Health and Care Research.

Moreover, in February 2022, Coloplast, one of the world's leading manufacturers of stoma care products launched its latest product innovation, the SenSura Mio in Singapore this year. Singapore is the first country in Southeast Asia that launch SenSura Mio which aims to improve the quality of life of ostomates, or people who have gone through ostomy and are now living with stoma.

Furthermore, the rise in the prevalence of inflammatory bowel diseases, the increasing geriatric population, the launch of various bowel management products, recent and new potential approvals, and Favorable reimbursement policies, will further drive the market growth during the forecast period.

Market Dynamics: Restraint

Patient preference for non-invasive clinical management of Fecal incontinence. Currently, Fecal incontinence can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter and the creation of a stoma. These often require long-term patient rehabilitation and also it is highly inconvenient and even severely painful.

Also, lack of awareness, regulatory concerns, and concerned side effects are also the factors that hamper the market growth rate during the forecast period.

Segment Analysis

The global bowel management systems is segmented based on product type, application, patient type, end-user and region.

The colostomy bags from the product type segment accounted for approximately 41.2% of the market share

The colostomy bags from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A colostomy bag is a plastic bag that collects faecal matter, also called stool or poop, from the digestive tract through an opening in the abdominal wall called a stoma. Doctors attach a bag to the stoma following a colostomy operation.

A colostomy bag, also called a stoma bag or ostomy bag, is a small, waterproof pouch used to collect waste from the body. During a surgical procedure known as a colostomy, an opening called a stoma or ostomy is formed between the large intestine (colon) and the abdominal wall. This allows waste products to be excreted through the opening in the abdominal wall rather than via the colon through the rectum and anus.

For instance, in December 2021, Coloplast launched a clinical trial to test the effect of its ostomy product, Heylo, a product that uses sensors to warn patients with colostomy bags about leakage and advise them about how to prevent it. Thus, the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors such as the rising prevalence of colorectal cancer and the growing geriatric population. Additionally, increased patient awareness, rising adoption rates of intestinal management systems, increasing investments in product development, excellently established healthcare infrastructure, and strong acceptance of developed products are some of the key factors ensuring the region's dominance.

For instance, in May 2023 Advanced Medical Balloons GmbH (formerly Creative Balloons GmbH), a specialist in medical technology from Waghaeusel near Heidelberg, stated that the company is expanding its intensive care business to the United States.

This is based on the approval which has recently been granted by the U.S. Food and Drug Administration (FDA) for their innovative catheter system hygh-tec. The novel faecal management system hygh-tec provides maximum seal and prevention of faecal leakage in patients receiving intensive care.

Moreover, in July 2021 Trio Healthcare secured a second round of funding from US specialist finance company, SWK Holdings Corporation. The funding, approximately $10m in total, will support Trio's R&D and manufacturing as it scales up operations to support a large-scale global roll-out of Trio's world-first stoma bag, GeniiTM

COVID-19 Impact Analysis

COVID-19 had a substantial impact on bowel management systems. Amidst the outbreak of the COVID-19 pandemic, there has been a rise in other health complications that rose with COVID-19 infections. According to a report by the surveillance epidemiology of coronavirus Under Research Exclusion (SECURE-IBD) database published in January 2022 mentioned that adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with inflammatory bowel disease (IBD).

Competitive Landscape

The major global players in the bowel management systems market include: Becton, Dickinson and Company, Coloplast Pty Ltd., ConvaTec Group plc., B Braun SE., Consure Medical Pvt. Ltd., GBUK Group Ltd., Wellandmedical, Wellspect, ProSys International Ltd Qufora and among others.

Key Developments

In April 2022, Microbiotica received project funding from the crohn's and colitis foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
In November 2021, Medtronic plc, a global leader in healthcare technology, stated that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes.
In May 2021, Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, stated European CE Mark approval of its second-generation Axonics r-SNM implantable neurostimulator (INS) and wireless patient remote control with SmartMRI technology.

Why Purchase the Report?

To visualize the global bowel management systems market segmentation-based product type, application, patient type, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analysing trends and co-development
Excel data sheet with numerous data points of bowel management systems market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global bowel management systems market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Patient Type
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Driver
  - 4.1.1.1. Rise in the technology advancements
  - 4.1.1.2. Rise in the product launches by key players
- 4.1.2. Restraints
  - 4.1.2.1. Long-term patient rehabilitation
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Colostomy Bags*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Irrigation Systems
7.4. Nerve Modulation Devices
7.5. Others

8. By Patient Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 8.1.2. Market Attractiveness Index, By Patient Type
8.2. Adults*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Pediatric

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Spinal Cord Injury*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Neurological Disorders
9.4. Multiple Sclerosis
9.5. Stroke

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers (ASCs)
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Becton, Dickinson and Company
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Coloplast Pty Ltd.
13.3. ConvaTec Group plc.
13.4. B Braun SE.
13.5. Consure Medical Pvt. Ltd.
13.6. GBUK Group Ltd.
13.7. Wellandmedical
13.8. Wellspect
13.9. ProSys International Ltd
13.10. Qufora

LIST NOT EXHAUSTIVE